SGCG and neoplasm: Immunoreactive tumours also display proinflammatory cytokines (i.e., tumour necrosis factor (TNF)α, type I and type II interferon (IFN), and interleukin (IL)-23, IL-22, and IL-1β) that should establish a suitable environment for T cell fitness and activation and possess a higher mutational burden compared to that of other cancer subtypes, and this can act as a source of tumour-associated antigens to prime anti-tumour T cells [15,16,17].